| Literature DB >> 32060847 |
Sherven Sharma1,2,3, Pournima Kadam4, Steven Dubinett5,4,6.
Abstract
CCL21 promotes immune activity in the tumor microenvironment (TME) by colocalizing dendritic cells (DC) and T cells programing ectopic lymph node architectural structures that correlate with cancer prognosis. Innovative strategies to deliver CCL21 in cancer patients will reactivate the downregulated immune activity in the TME. Immune escape mechanisms are upregulated in the TME that promote tumor immune evasion. CCL21 combined with inhibition of dominant pathways of immune evasion will aid in the development of effective immunotherapy for cancer.Entities:
Keywords: Activated T cells; Antigen-presenting cells; CCL21; Dendritic cells; Immune activity; Immune checkpoint blockade; Immune suppression; Immunotherapy; Programmed cell death protein 1 (PD-1); T cells; Tumor microenvironment
Mesh:
Substances:
Year: 2020 PMID: 32060847 DOI: 10.1007/978-3-030-36667-4_7
Source DB: PubMed Journal: Adv Exp Med Biol ISSN: 0065-2598 Impact factor: 2.622